These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 15636678)
1. Highlights from the 29th European Society for Medical Oncology Congress: Vienna, Austria, October 29 through November 2, 2004. Price N Clin Prostate Cancer; 2004 Dec; 3(3):136-40. PubMed ID: 15636678 [No Abstract] [Full Text] [Related]
2. [Current chemo- and hormone therapy in disseminated malignant melanoma of the skin]. Akimov MA; Gershanovich ML Vopr Onkol; 1999; 45(4):341-9. PubMed ID: 10532089 [No Abstract] [Full Text] [Related]
3. [Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004]. Mazeron JJ; Cancer Radiother; 2005 Mar; 9(2):122-6. PubMed ID: 15820439 [No Abstract] [Full Text] [Related]
4. Prostate cancer chemotherapy: emerging from the shadows. Roth BJ J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529 [No Abstract] [Full Text] [Related]
5. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. Masters GA; Krilov L; Bailey HH; Brose MS; Burstein H; Diller LR; Dizon DS; Fine HA; Kalemkerian GP; Moasser M; Neuss MN; O'Day SJ; Odenike O; Ryan CJ; Schilsky RL; Schwartz GK; Venook AP; Wong SL; Patel JD J Clin Oncol; 2015 Mar; 33(7):786-809. PubMed ID: 25605863 [No Abstract] [Full Text] [Related]
6. [Development of cancer chemotherapy. The discovery of new active drugs. II]. Lopez M Clin Ter; 1998; 149(6):453-9. PubMed ID: 10100409 [No Abstract] [Full Text] [Related]
7. Highlights from the 39th Annual meeting of the American Society of Clinical Oncology Chicago, Illinois. Tyagi P; Klem J; D'Orazio A Clin Prostate Cancer; 2003 Sep; 2(2):73-9. PubMed ID: 15040866 [No Abstract] [Full Text] [Related]
8. Time for a neoadjuvant chemotherapy strategy in prostate cancer? Walther PJ Curr Opin Urol; 2000 May; 10(3):225-7. PubMed ID: 10858901 [No Abstract] [Full Text] [Related]
9. Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology, May 2005, and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, February 2005, Orlando, Florida. Reddy GK; Tyagi P Clin Prostate Cancer; 2005 Jun; 4(1):7-14. PubMed ID: 15992456 [No Abstract] [Full Text] [Related]
10. Hormone-refractory prostate cancer: what have we learned? Wirth MP BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362 [No Abstract] [Full Text] [Related]
12. Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. June 2004. Lee D; Price N; Reddy K Clin Prostate Cancer; 2004 Sep; 3(2):73-6. PubMed ID: 15479487 [No Abstract] [Full Text] [Related]
13. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Moul JW Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788 [No Abstract] [Full Text] [Related]
14. Is chemotherapy ready for clinical use in prostatic cancer patients? Jones WG Prog Clin Biol Res; 1988; 269():159-76. PubMed ID: 3293058 [No Abstract] [Full Text] [Related]
15. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Sava T; Basso U; Porcaro A; Cetto GL Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438 [TBL] [Abstract][Full Text] [Related]
16. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer. Di Silverio F; Serio M; Costantini A J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846 [No Abstract] [Full Text] [Related]